Shares of StemCells, Inc.(NASDAQ:STEM) soared 11
percent to $2.17 on Friday, rising for the second consecutive day after the
biotech group announced its plans to present data from a Phase I/II clinical
trial testing its stem-cell therapy in the treatment of chronic spinal-cord
injuries.
The data will be presented on Monday, Sept. 3, at the
annual scientific meeting of the International Spinal Cord Society in London.
StemCells plans to hold a conference call for
interested parties the following day to discuss the data. The stock has risen 6
percent in the last 30 days, and has soared 128 percent since the beginning of
the year.
The presentation will include interim data from the
study`s first cohort, which has three partially paralyzed patients being
treated with STEM`s proprietary HuCNS-SC cells, the company said in a statement
on Thursday.
Find Out How
Should investors Trade STEM Now Here
Researchers are looking for efficacy - measured by
improvement in motor function, sensation, and bladder control - and safety in
the first of three planned cohorts, each with more mild paralysis than the
previous.
Analysts are expecting some positive results from the
trial. If Monday`s data looks good for STEM, shares may climb higher on
momentum, however, negative results will have disastrous effects on the stock.
StemCells is engaged in the research, development, and
commercialization of cell-based therapeutics and tools for use in stem
cell-based research and drug discovery.
The company's lead therapeutic product candidate,
HuCNS-SC(R) cells (purified human neural stem cells), is currently in
development as a potential treatment for a broad range of central nervous
system disorders.
In a Phase I clinical trial in Pelizaeus-Merzbacher
disease (PMD), a fatal myelination disorder in children, and the company has
shown preliminary evidence of progressive and durable donor-derived myelination
in all four patients transplanted with HuCNS-SC cells.
The company is also conducting a Phase I/II clinical
trial in chronic spinal cord injury in Switzerland and has reported positive
interim safety data for the first patient cohort.
No comments:
Post a Comment